Illumina $7.1B deal for Grail sent back to FTC by appeals court

Sundry Photography/iStock Editorial via Getty Images

Illumina’s (NASDAQ:ILMN) planned $7.1 billion purchase of cancer test developer Grail was sent back to the Federal Trade Commission by a U.S. appeals court, who still determined that the regulator was correct in finding the deal anticompetitive.

The Fifth Circuit

7.1BappealsCourtDealFTCGrailIllumina
Comments (0)
Add Comment